Catarina Novalio

Radiation Oncologist @ Instituto Português de Oncologia de Lisboa 🇵🇹

[PDBrown @PDBrownOnc]

🚨🚨 ASCO 2026 Final Results Randomized trial resected brain met Brachytherapy vs Post-Op SRS🚨
- Incredible Surg Bed Control with Brachy (↑↑OS as well)
- Surg bed recurrence 12% SRS vs 1% GammaTile

[Pierre Blanchard, MD @PBlanchardMD]

Yesterday, I presented the @GETUG_Unicancer PEACE 2 trial at #ESTRO26 on the role of pelvic RT in very high risk #prostatecancer pts (staged with conventional imaging).

Twittorial below

Key conclusion: pelvic RT did not improve clinical outcomes (cPFS, MFS, PCSS, OS)...

1/n

[Hathal Haddad @Radiooncology]

🚀 10-year #FASTForward results confirm that 1-week breast radiotherapy (26 Gy/5 fractions) is safe, effective, and non-inferior to the traditional 3-week RT
✅ Lower local recurrence
✅ Acceptable late toxicity
🔗 https://t.co/5pu2bpSdqs

[Melek Tugce Yilmaz MD @mtugceyilmaz]

“For (almost) all!” @PBlanchardMD arguing in favor of treating the primary in both low and high volume disease! #ESTRO26

[UroToday.com @urotoday]

Long-term oncological outcomes of extended vs limited pelvic lymph node dissection during radical prostatectomy for intermediate- and high-risk #ProstateCancer: Phase 3 randomized controlled trial. Presentation by Jean Felipe Lestingi, MD @Icesp_. #AUA26 written coverage by @zklaassen_md @GACancerCenter > https://t.co/iEBPNH8Tnq @AmerUrological #AUA2026

[Oncology Brothers @OncBrothers]

TDXd now @US_FDA ✅ in neoadjuvant and adjuvant high risk residual HER2+ breast cancer based off DESTINYBreast05 and DESTINYBreast11:

- ⬆️ pCR & iDFS w/ TDXd
- Timings of RT did NOT impact the incidence or severity of ILD
- New Soc for high risk disease!

#bcsm #OncTwitter

[Daniel E Spratt @DrSpratticus]

For those that couldnt make it to #AUA26, especially those at #ESTRO26, here were some of the slides for the "Pro" RT to primary in M1a disease.

@TylerSbrt @UroCancer @CaPsurvivorship @PCaParker @Prof_Nick_James @wandering_gu

[Nicholas Zaorsky, MD MS @NicholasZaorsky]

My @ASTRO_org 2026 GU spring refresher extended "long-course" slide deck is available at
https://t.co/HND3LmzgZb

You can also watch the "short-course" 1.5 hour narrated version here:
https://t.co/GpDtfapF4K

[Nicholas Zaorsky, MD MS @NicholasZaorsky]

2026 Genitourinary Oncology Spring Refresher - Dry Run

Updates in the management of cancers of the prostate, bladder, kidney, testes, from @NCCN @ASTRO_org @ESTRO_RT @Uroweb

#Radonc residents @ARRO_org, I hope it helps you ace the board exams!

https://t.co/5X8nP1NX0j

[radoncreview_org @radoncreview]

Our “Best of” #ESTRO26 outline is now live! 🚀

What key studies are we missing?

Drop any important trials, abstracts, or presentations we should add 👇

https://t.co/MyeQVhxxSk

#RadOnc #ESTRO26 #ESTRO2026

[Piet Ost @piet_ost]

@TylerSbrt @PCaParker @urotoday @neerajaiims @huntsmancancer @TDorffOnc @cityofhope @ChrisSweens1 @DrSpratticus @Prof_Nick_James @BertrandTOMBAL The official response I got from the company is shocking: Allowing for radiation to the prostate (per STAMPEDE and/or PEACE) studies has the potential to confound the interpretability of the results, specifically the OS results which is a key alpha protected secondary endpoint.

[Aaron Newman Lab @AaronNewmanLab]

1/ Thrilled to share our new paper, out today in @Nature: "Non-invasive profiling of the tumour microenvironment with spatial ecotypes".

Paper (open access): https://t.co/EujZFqU7wi

[Advances, an ASTRO Journal @Advances_ASTRO]

📌Validation of IBS-GEC ESTRO-ABS CT Based Contouring Recommendations using Pre-Brachytherapy MRI in Cancer Cervix Patients Treated with Definitive Radiotherapy
🔗 https://t.co/dZodPchjsh @ASTRO_org
@HBCHRC_Punjab @DrShinghal @TMC_Varanasi
👉🏻 One of the largest series that compared CT and MR-based contouring using hybrid-interstitial applications in all patients for validating IBS-GEC ESTRO-ABS guidelines in MRDG – PreBTMR and CTBT environment.
👉🏻 CT based contouring using IBS-GEC ESTRO-ABS recommendations with MRI at diagnosis and brachytherapy, is safe, convenient and addresses logistic issues in institutions, especially LMICs.

[Dr Rupam Manna MD @DrRupamOncology]

🟣 Metastatic Endometrial Carcinoma Management — Latest Guideline-Based Approach (2025–2026)
Molecularly driven, personalized, and evidence-based:
✅ TCGA molecular classification (POLE, MSI-H/dMMR, NSMP, p53abn)
✅ First-line algorithms:
  • MSI-H → Chemo + Checkpoint inhibitor (RUBY / NRG-GY018)
  • pMMR/MSS → Carbo/Pac → Pembro + Lenvatinib (KEYNOTE-775)
  • HER2+ Serous → Carbo/Pac + Trastuzumab (Fader)
✅ Hormone therapy, CDK4/6 emerging options, targeted therapy table & more
High-yield quick reference every gyn-onc & medical oncologist needs!
Save for clinic | Share with your fellows & residents 👇
#Oncology #GynOnc #EndometrialCancer #OncoTwitter #MedEd #CancerCare #MedTwitter

[Glenn J. Hanna, M.D. @HeadNeckMD]

Sharing the results of ReACT 1.0 in @NatureComms -- the first study to use HPV ctDNA to guide CRT de-escalation in higher risk HPV+ OPC. ctDNA metrics may improve risk stratification. Grateful to our coauthors. @Naveris_inc @DanaFarberNews @jdschoenfeld1
https://t.co/53tHQtj8pl

[Aya Mohamed | MSc, MD 🎗 @Dr_Oncologista]

TROPION-Breast02:

Dato-DXd redefines 1L mTNBC beyond efficacy alone.
A near 3-fold prolongation in QoL preservation vs chemotherapy (TTD 23.5 vs 8.3 mo; HR 0.64) signals a paradigm shift toward "quality survival"

#ESMOBreast26 @OncoAlert #mTNBC #ADCs #bcsm

[Yakup Ergün @dr_yakupergun]

#ESMOBreast26
Treatment Optimization in early HR+/HER2− BC

Low-risk: ET
High-risk: chemo + ET + CDK4/6i

The unresolved question is the intermediate-risk group:
There is no definitive answer yet, but for now, decisions can be guided by indirect evidence and individualized risk assessment

[ESTRO @ESTRO_RT]

Published in the #GreenJournal: ESTRO clinical practice #guideline on #radiotherapy for adult soft tissue #sarcoma of the extremities and trunk wall – Endorsed by @ASTRO_org
👉 https://t.co/blP0yOVZHj

[Yakup Ergün @dr_yakupergun]

Axillary surgery → CDK4/6 eligibility: what’s the real gain?

🔍5 RCTs, n=19,541
➡️Patients needed to prevent 1 event:
→ iDFS: 106–123
→ DDFS: 119–129
→ OS: 345–807

CDK4/6 benefit exists, but:
→ Grade ≥3 AEs: ~50–60%
→ ↑ Lymphedema: +3.9% (SLNB), +10.6% (cALND)

💬Using axillary surgery solely to guide CDK4/6 therapy → high NNT, added morbidity, marginal OS gain

https://t.co/PvOVn2VDSX

[Yakup Ergün @dr_yakupergun]

Simultaneous publication with #ESMOBreast26

An excellent de-escalation study: PHERGain-2 study

A chemotherapy-free, pathological response-adapted strategy using trastuzumab–pertuzumab and T-DM1 in HER2-positive early breast cancer

https://t.co/3XmXpbc7UN